ReNeuron Group (RENE.L) announced the placing of 94.4 M new ordinary shares with existing and new institutional and qualifying individual shareholders on 2/22/10. This placement was comprised 2 closings and will trade on AIM.
Shares of Amylin Pharma (NASDAQ: AMLN) are rising by about 10% during early trading today on the issuance of a Complete Response Letter (CRL) from FDA for its once-weekly formulation of its diabetes drug Byetta (exenatide), which would be marketed as Bydureon. The issues raised in the CRL appear to be minor and related to labeling issues with expected resubmission in the next few weeks and likely Class I (60-day) review designation by the FDA upon resubmission by AMLN. Eli Lilly (NYSE: LLY) and Alkermes (NASDAQ: ALKS) also have stakes in the drug, with ALKS also trading up 10% and LLY up slightly during early trading.
Reported a lower FY09 net loss of $23.216 M or $0.65 per share with higher revenues versus a net loss of $30.036 M, or $1.12 per share for FY08.
Reported a smaller FY09 net loss of $27.02 M or $0.25 per share, an increase in revenues but, increased operational losses; versus a net loss of $29.08 M, or $0.35 per share for 2008.
HavRx Global Crop Science Index: Potash (NYSE: POT) is poised to open trading at new highs after posting strong earnings and upping its guidance. Meanwhile, Yara International (OTC: YARIY.PK) has withdrawn its bid for Terra Industries (NYSE: TRA), which will be acquired by CF Industries (NYSE: CF). In addition, Agrium (NYSE: AGU) has dropped its hostile bid for CF.
Biotime (BTIM) reported (3/10/10) a FY09 net loss $5.14 M or $0.18 per diluted share compared to a $3.8 M or $0.16 per diluted share in FY08 .
We are all looking for any signal that will propel a stock and ONE indicator is the CEO investing his own money in ASTMD. CEO’s “direct” share ownership should be a factor of significance, but should not be confused with option or grant holdings. Timothy Mayleben, the new CEO filed a Form 4, this week with the SEC. Read more…
Opexa Therapeutics reported (3/5/10) a net loss of $1.43 M or $0.11 per diluted share for FY09 compared to $11.85 M or $1.12 per diluted share in FY08. FY09 highlights:
ASTMD reported the final patient treatment in the ongoing cardiac regeneration US P 2 surgical clinical trial designated IMPACT-DCM. Treated at Emory University Hospital Midtown in Atlanta, GA, this patient received direct injections of ASTMD’s tissue repair cells for the treatment of dilated cardiomyopathy (DCM), a severe form of congestive heart failure in which the heart becomes weakened and enlarged and cannot pump blood efficiently.
ASTMD has regained compliance with the $1.00 minimum bid price requirement under the NASDAQ Listing Rule.
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.